"Oligopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides composed of between two and twelve amino acids.
| Descriptor ID |
D009842
|
| MeSH Number(s) |
D12.644.456
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligopeptides".
Below are MeSH descriptors whose meaning is more specific than "Oligopeptides".
This graph shows the total number of publications written about "Oligopeptides" by people in this website by year, and whether "Oligopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 2 | 2 |
| 1994 | 1 | 2 | 3 |
| 1995 | 3 | 0 | 3 |
| 1996 | 3 | 1 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 3 | 4 |
| 1999 | 3 | 2 | 5 |
| 2000 | 0 | 4 | 4 |
| 2001 | 2 | 2 | 4 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 4 | 5 |
| 2005 | 4 | 0 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 4 | 1 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 3 | 5 |
| 2011 | 5 | 2 | 7 |
| 2012 | 5 | 7 | 12 |
| 2013 | 3 | 5 | 8 |
| 2014 | 8 | 2 | 10 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 4 | 6 |
| 2017 | 6 | 3 | 9 |
| 2018 | 2 | 0 | 2 |
| 2019 | 4 | 3 | 7 |
| 2020 | 0 | 4 | 4 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oligopeptides" by people in Profiles.
-
A case of reactive granulomatous dermatitis associated with neonatal lupus erythematosus. J Cutan Pathol. 2023 Sep; 50(9):793-797.
-
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leuk Lymphoma. 2022 10; 63(10):2413-2421.
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 01; 23(1):65-76.
-
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 10 12; 5(19):3748-3759.
-
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.
-
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):701-710.
-
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
-
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020 12; 21(12):e540.
-
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
-
Determining Whether Agonist Density or Agonist Number Is More Important for Immune Activation via Micoparticle Based Assay. Front Immunol. 2020; 11:642.